NASDAQ:GALT

Galectin Therapeutics News Headlines

$3.64
-0.11 (-2.93 %)
(As of 06/14/2021 11:45 AM ET)
Add
Compare
Today's Range
$3.64
$3.83
50-Day Range
$2.07
$5.10
52-Week Range
$1.82
$5.70
Volume8,086 shs
Average Volume1.64 million shs
Market Capitalization$211.47 million
P/E RatioN/A
Dividend YieldN/A
Beta2.35

Galectin Therapeutics (NASDAQ GALT) News Headlines Today

SourceHeadline
Is Galectin Therapeutics Inc. (GALT) A Good Stock To Buy?Is Galectin Therapeutics Inc. (GALT) A Good Stock To Buy?
finance.yahoo.com - June 13 at 11:31 PM
-$0.18 EPS Expected for Galectin Therapeutics Inc. (NASDAQ:GALT) This Quarter-$0.18 EPS Expected for Galectin Therapeutics Inc. (NASDAQ:GALT) This Quarter
americanbankingnews.com - May 31 at 11:24 AM
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business UpdateGalectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business Update
finance.yahoo.com - May 17 at 8:30 AM
Galectin Therapeutics to Present at 4th Global NASH CongressGalectin Therapeutics to Present at 4th Global NASH Congress
finance.yahoo.com - April 27 at 1:05 PM
World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin Therapeutics as Special Consultant to Accelerate and Enhance Development of Company’s Galectin-3 Inhibitor, BelapectinWorld-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin Therapeutics as Special Consultant to Accelerate and Enhance Development of Company’s Galectin-3 Inhibitor, Belapectin
finance.yahoo.com - April 19 at 9:29 AM
Have Insiders Been Selling Galectin Therapeutics Inc. (NASDAQ:GALT) Shares?Have Insiders Been Selling Galectin Therapeutics Inc. (NASDAQ:GALT) Shares?
nasdaq.com - April 18 at 10:55 PM
Company News for Apr 15, 2021Company News for Apr 15, 2021
finance.yahoo.com - April 15 at 12:45 PM
Whats Going On With GALT Stock And TV Stock Today?What's Going On With GALT Stock And TV Stock Today?
benzinga.com - April 14 at 3:58 PM
Galectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor ResponseGalectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor Response
finance.yahoo.com - April 14 at 3:58 PM
Galectin Gains on Product NewsGalectin Gains on Product News
baystreet.ca - April 14 at 10:58 AM
Journal for ImmunoTherapy of Cancer Publishes...Journal for ImmunoTherapy of Cancer Publishes...
benzinga.com - April 14 at 12:56 AM
Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 TherapyJournal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy
finance.yahoo.com - April 13 at 7:55 PM
Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis StudyGalectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis Study
finance.yahoo.com - April 6 at 9:28 AM
Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business UpdateGalectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update
finance.yahoo.com - March 31 at 1:01 PM
OncoImmunology Publishes Pre-clinical Research Showing Galectin Therapeutics’ Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 TherapyOncoImmunology Publishes Pre-clinical Research Showing Galectin Therapeutics’ Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 Therapy
finance.yahoo.com - March 8 at 11:34 AM
Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences ConferenceGalectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 4 at 12:28 PM
Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences ConferenceGalectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 4 at 12:28 PM
What Kind Of Investors Own Most Of Galectin Therapeutics, Inc. (NASDAQ:GALT)?What Kind Of Investors Own Most Of Galectin Therapeutics, Inc. (NASDAQ:GALT)?
finance.yahoo.com - January 31 at 9:00 AM
Insider Sells Galectin Therapeutics StockInsider Sells Galectin Therapeutics Stock
finance.yahoo.com - January 19 at 6:00 PM
GALT Jan 2021 10.000 putGALT Jan 2021 10.000 put
uk.finance.yahoo.com - January 1 at 11:21 PM
Galectin Therapeutics Inc. Common Stock (GALT)Galectin Therapeutics Inc. Common Stock (GALT)
nasdaq.com - December 18 at 9:18 PM
Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020
finance.yahoo.com - December 11 at 8:19 AM
Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders PresentationGalectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders Presentation
finance.yahoo.com - December 4 at 5:55 PM
Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of StockholdersGalectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders
finance.yahoo.com - December 1 at 5:10 PM
GALT Dec 2020 4.000 callGALT Dec 2020 4.000 call
uk.finance.yahoo.com - November 29 at 2:43 AM
GALT Dec 2020 5.000 callGALT Dec 2020 5.000 call
uk.finance.yahoo.com - November 27 at 3:17 PM
Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020
finance.yahoo.com - November 9 at 12:38 PM
GALT Nov 2020 2.000 callGALT Nov 2020 2.000 call
uk.finance.yahoo.com - November 2 at 2:36 PM
GALT Nov 2020 3.000 callGALT Nov 2020 3.000 call
uk.finance.yahoo.com - November 2 at 9:35 AM
Galectin Therapeutics (NASDAQ:GALT) Is In A Good Position To Deliver On Growth PlansGalectin Therapeutics (NASDAQ:GALT) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - November 2 at 9:35 AM
GALT Nov 2020 1.000 callGALT Nov 2020 1.000 call
uk.finance.yahoo.com - November 1 at 11:32 PM
Galectin Therapeutics Investor Conference Call and Webinar Taking Place TodayGalectin Therapeutics Investor Conference Call and Webinar Taking Place Today
markets.businessinsider.com - September 29 at 12:27 PM
Galectin TherapeuticsGalectin Therapeutics
fool.com - September 16 at 7:54 PM
Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
finance.yahoo.com - September 10 at 11:17 AM
Insider Buys Galectin Therapeutics StockInsider Buys Galectin Therapeutics Stock
finance.yahoo.com - September 9 at 2:56 PM
GALT Aug 2020 3.000 callGALT Aug 2020 3.000 call
ca.finance.yahoo.com - August 22 at 7:32 AM
GALT Jan 2021 5.000 callGALT Jan 2021 5.000 call
ca.finance.yahoo.com - August 20 at 8:14 AM
GALT Aug 2020 2.000 callGALT Aug 2020 2.000 call
ca.finance.yahoo.com - August 19 at 9:51 AM
GALT Sep 2020 3.000 callGALT Sep 2020 3.000 call
ca.finance.yahoo.com - August 19 at 9:50 AM
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business UpdateGalectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business Update
finance.yahoo.com - August 10 at 12:38 PM
Is Galectin Therapeutics, Inc.'s (NASDAQ:GALT) Shareholder Ownership Skewed Towards Insiders?Is Galectin Therapeutics, Inc.'s (NASDAQ:GALT) Shareholder Ownership Skewed Towards Insiders?
finance.yahoo.com - August 3 at 1:21 PM
Galectin Therapeutics (GALT) StockGalectin Therapeutics (GALT) Stock
markets.businessinsider.com - July 17 at 9:12 AM
Intercepts Pain Is Galectins Gain: Clinical Outcomes In NASH Are CrucialIntercept's Pain Is Galectin's Gain: Clinical Outcomes In NASH Are Crucial
seekingalpha.com - July 7 at 9:35 AM
Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in CancerGalectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer
www.bloomberg.com - July 6 at 11:33 PM
Galectin launches new study of lead drug in NASHGalectin launches new study of lead drug in NASH
seekingalpha.com - June 30 at 1:18 PM
Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH CirrhosisGalectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis
finance.yahoo.com - June 30 at 1:18 PM
UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH CirrhosisUPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis
finance.yahoo.com - June 30 at 1:18 PM
Galectin Therapeutics Shares March Higher, Can It Continue?Galectin Therapeutics' Shares March Higher, Can It Continue?
finance.yahoo.com - May 22 at 12:37 PM
GALT Galectin Therapeutics Inc. Common StockGALT Galectin Therapeutics Inc. Common Stock
www.nasdaq.com - May 20 at 11:43 PM
Galectin Therapeutics EPS beats by $0.03Galectin Therapeutics EPS beats by $0.03
seekingalpha.com - May 11 at 5:29 PM
This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.